Digital technologies meet cost containment in the new pharma marketing landscape, writes Bill Drummy.
The slow evolution toward a state of grace in tracking ROI for digital promotion.
Why, with all the data available, is pharma so bad at getting true marketing insights to drive its business? Bill Drummy looks at how to realize the promise of "Big Data".
While what is considered 'traditional' marketing has evolved over the years, it's clear that a digital strategy is an absolute necessity to compete today—not just tomorrow.
It's a disturbing irony: In an industry whose entire economic value is founded on its ability to innovate, why is there so much discomfort with the risk required for innovation. Where did the courage to innovate go?
The bigger the company, the thicker the sclerosis, the more they need to suck out the fat
Keeping your finger on the pulse of consumers leads to better, more actionable insights—and better results.
Does Big Pharma have the emotional connection and intellectual commitment to move with the pace of change?
Web site supports Crohn's patients and supplies goal-busting database for company's new product
Supply Chain Strategy: Managing risk and opportunity in a changing global landscape
Sponsored By PricewaterhouseCoopers LLP Optimizing the Multi-Sponsor REMS Experience (Risk Evaluation & Mitigation Strategies)
Sponsored By PricewaterhouseCoopers LLP Effective Resource Planning: Reducing Clinical Project Risk and Operating Cost
Sponsored By ClearTrial